MA31761B1 - Nouveaux inhibiteurs de seh et leur utilisation - Google Patents
Nouveaux inhibiteurs de seh et leur utilisationInfo
- Publication number
- MA31761B1 MA31761B1 MA32751A MA32751A MA31761B1 MA 31761 B1 MA31761 B1 MA 31761B1 MA 32751 A MA32751 A MA 32751A MA 32751 A MA32751 A MA 32751A MA 31761 B1 MA31761 B1 MA 31761B1
- Authority
- MA
- Morocco
- Prior art keywords
- seh
- relates
- compounds
- compound
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/46—Phenazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne de nouveaux inhibiteurs de seh et leur utilisation dans le traitement de maladies médiées par l'enzyme seh. De façon spécifique, l'invention concerne des composés répondant à la formule i : r1, r2, r5, r6, a, b, y, z, n, et m étant définis ci-après, et des sels pharmaceutiquement acceptables de ces composés. Les composés de l'invention sont des inhibiteurs de seh et peuvent être utilisés dans le traitement de maladies médiées par l'enzyme seh, telles que l'hypertension. Par conséquent, l'invention concerne également des compositions pharmaceutiques contenant un composé de l'invention. L'invention concerne de plus des procédés d'inhibition de seh et le traitement de pathologies y étant associées au moyen d'un composé de l'invention ou d'une composition pharmaceutique contenant un composé de l'invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97915407P | 2007-10-11 | 2007-10-11 | |
PCT/US2008/079517 WO2009049157A1 (fr) | 2007-10-11 | 2008-10-10 | Nouveaux inhibiteurs de seh et leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31761B1 true MA31761B1 (fr) | 2010-10-01 |
Family
ID=40549589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32751A MA31761B1 (fr) | 2007-10-11 | 2010-04-08 | Nouveaux inhibiteurs de seh et leur utilisation |
Country Status (29)
Country | Link |
---|---|
US (2) | US8173805B2 (fr) |
EP (1) | EP2214487B1 (fr) |
JP (1) | JP5372943B2 (fr) |
KR (1) | KR101546111B1 (fr) |
CN (1) | CN101896065B (fr) |
AU (1) | AU2008310732B2 (fr) |
BR (1) | BRPI0817542A2 (fr) |
CA (1) | CA2702265C (fr) |
CO (1) | CO6270285A2 (fr) |
CR (1) | CR11423A (fr) |
CY (1) | CY1114865T1 (fr) |
DK (1) | DK2214487T3 (fr) |
DO (1) | DOP2010000101A (fr) |
EA (1) | EA018414B1 (fr) |
ES (1) | ES2445444T3 (fr) |
HK (1) | HK1141211A1 (fr) |
HR (1) | HRP20140105T1 (fr) |
IL (1) | IL204889A (fr) |
MA (1) | MA31761B1 (fr) |
MX (1) | MX2010003942A (fr) |
MY (1) | MY157116A (fr) |
NZ (1) | NZ584471A (fr) |
PL (1) | PL2214487T3 (fr) |
PT (1) | PT2214487E (fr) |
RS (1) | RS53180B (fr) |
SI (1) | SI2214487T1 (fr) |
UA (1) | UA107444C2 (fr) |
WO (1) | WO2009049157A1 (fr) |
ZA (1) | ZA201002465B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008105968A1 (fr) | 2006-11-03 | 2008-09-04 | Smithkline Beecham Corporation | Nouveaux inhibiteurs de seh et utilisation de ces derniers |
MX2010003942A (es) | 2007-10-11 | 2010-04-30 | Glaxosmithkline Llc | Nuevos inhibidores de epoxido hidrolasa soluble y su uso. |
WO2009049165A1 (fr) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Inhibiteurs inédits de la seh et leur utilisation |
FR2948027A1 (fr) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
WO2015003360A2 (fr) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Composés thérapeutiquement actifs et leurs méthodes d'utilisation |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015104422A1 (fr) | 2014-01-13 | 2015-07-16 | Basf Se | Composés dihydrothiophène dans la lutte contre des nuisibles invertébrés |
WO2015155129A1 (fr) * | 2014-04-07 | 2015-10-15 | Basf Se | Composé de diaminotriazine |
US10308648B2 (en) * | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2024105225A1 (fr) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur |
WO2024105234A1 (fr) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Inhibiteurs doubles de récepteur sigma-1 et d'époxyde hydrolase soluble et leur utilisation dans le traitement de la douleur |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5420283A (en) | 1993-08-02 | 1995-05-30 | Pfizer Inc. | Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide |
CA2320730A1 (fr) | 1998-12-23 | 2000-07-06 | Renhua Li | Inhibiteurs du facteur xa ou de la thrombine |
AU2001273212A1 (en) | 2000-07-07 | 2002-01-21 | Neotherapeutics, Inc. | Methods for treatment of drug-induced peripheral neuropathy and related conditions |
US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
ES2282299T3 (es) | 2000-10-20 | 2007-10-16 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos. |
WO2002058736A2 (fr) | 2000-12-12 | 2002-08-01 | Neotherapetics, Inc. | Utilisation d'analogues de purine a substitution en position 9 et d'autres molecules pour stimuler la neurogenese |
MXPA03005610A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
ES2292770T3 (es) | 2001-06-29 | 2008-03-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Derivados de fenilpirazoles en calidad de inhibidores de epoxido hidrolasa solubles. |
US20030055249A1 (en) | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CN1625410A (zh) | 2002-02-05 | 2005-06-08 | 山之内制药株式会社 | 2,4,6-三氨基-1,3,5-三嗪衍生物 |
WO2003097050A2 (fr) | 2002-05-16 | 2003-11-27 | Pharmacia Corporation | Methodes de traitement de maladies et de troubles respiratoires avec un inhibiteur inos selectif et un inhibiteur pde et compositions a cet effet |
EP1464335A3 (fr) | 2003-03-31 | 2007-05-09 | Taisho Pharmaceutical Co. Ltd. | Derivés de quinolines, tetrahydroquinolines et pyrimidines comme antagonistes du MCH |
CA2531061A1 (fr) | 2003-07-02 | 2005-01-13 | Vertex Pharmaceuticals Incorporated | Pyrimidines utilisees comme modulateurs des canaux ioniques sensibles au voltage |
US7223759B2 (en) * | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
US7547693B2 (en) | 2003-09-22 | 2009-06-16 | Banyu Pharmaceutical Co. Ltd. | Piperidine derivative |
GB0401269D0 (en) | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
AU2005289426A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
US20060142572A1 (en) | 2004-12-14 | 2006-06-29 | Gabriel Martinez-Botella | Inhibitors of ERK protein kinase and uses thereof |
JP2008540433A (ja) | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシドヒドロラーゼインヒビター及びその使用方法 |
EP1934182A1 (fr) * | 2005-10-07 | 2008-06-25 | Boehringer Ingelheim International Gmbh | Composés de pyridinone ou pyrimidinone n-substitués utiles en tant qu'inhibiteurs d'époxyde hydrolase soluble |
EP1987004A2 (fr) * | 2006-02-16 | 2008-11-05 | Boehringer Ingelheim International GmbH | Pyridineamides substitués pouvant être employés en tant qu'inhibiteurs d'époxyde hydrolase soluble |
AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
WO2008105968A1 (fr) * | 2006-11-03 | 2008-09-04 | Smithkline Beecham Corporation | Nouveaux inhibiteurs de seh et utilisation de ces derniers |
MX2010003942A (es) | 2007-10-11 | 2010-04-30 | Glaxosmithkline Llc | Nuevos inhibidores de epoxido hidrolasa soluble y su uso. |
WO2009049165A1 (fr) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Inhibiteurs inédits de la seh et leur utilisation |
WO2009049154A1 (fr) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Nouveaux inhibiteurs de seh et leur utilisation |
JPWO2009048154A1 (ja) | 2007-10-12 | 2011-02-24 | 日本電気株式会社 | 半導体装置及びその設計方法 |
WO2009070497A1 (fr) | 2007-11-28 | 2009-06-04 | Smithkline Beecham Corporation | Inhibiteurs de ehs et de 11β-hsd1 et leur utilisation |
JP2011506333A (ja) | 2007-12-06 | 2011-03-03 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規sEH阻害剤およびその使用 |
US20100311776A1 (en) | 2008-01-30 | 2010-12-09 | Smithkline Beecham Corporation | Novel sEH Inhibitors and their Use |
EP2240025A4 (fr) | 2008-01-30 | 2012-03-28 | Glaxosmithkline Llc | NOUVEAUX INHIBITEURS DE sEH ET LEUR UTILISATION |
EP2240021A4 (fr) | 2008-01-30 | 2011-08-17 | Glaxosmithkline Llc | Nouveaux inhibiteurs de seh et leur utilisation |
WO2010011917A1 (fr) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Llc | Inhibiteurs doubles de seh et 11β-hsd1 |
-
2008
- 2008-10-10 MX MX2010003942A patent/MX2010003942A/es active IP Right Grant
- 2008-10-10 SI SI200831142T patent/SI2214487T1/sl unknown
- 2008-10-10 WO PCT/US2008/079517 patent/WO2009049157A1/fr active Application Filing
- 2008-10-10 AU AU2008310732A patent/AU2008310732B2/en active Active
- 2008-10-10 PT PT88383146T patent/PT2214487E/pt unknown
- 2008-10-10 RS RS20140078A patent/RS53180B/en unknown
- 2008-10-10 CN CN200880120430XA patent/CN101896065B/zh active Active
- 2008-10-10 CA CA2702265A patent/CA2702265C/fr active Active
- 2008-10-10 EP EP08838314.6A patent/EP2214487B1/fr active Active
- 2008-10-10 US US12/682,073 patent/US8173805B2/en active Active
- 2008-10-10 UA UAA201005720A patent/UA107444C2/uk unknown
- 2008-10-10 KR KR1020107010233A patent/KR101546111B1/ko active IP Right Grant
- 2008-10-10 JP JP2010529081A patent/JP5372943B2/ja active Active
- 2008-10-10 PL PL08838314T patent/PL2214487T3/pl unknown
- 2008-10-10 DK DK08838314.6T patent/DK2214487T3/da active
- 2008-10-10 MY MYPI2010001613A patent/MY157116A/en unknown
- 2008-10-10 NZ NZ584471A patent/NZ584471A/en unknown
- 2008-10-10 ES ES08838314.6T patent/ES2445444T3/es active Active
- 2008-10-10 BR BRPI0817542-0A2A patent/BRPI0817542A2/pt active Search and Examination
- 2008-10-10 EA EA201070442A patent/EA018414B1/ru not_active IP Right Cessation
-
2010
- 2010-04-06 IL IL204889A patent/IL204889A/en active IP Right Grant
- 2010-04-08 MA MA32751A patent/MA31761B1/fr unknown
- 2010-04-08 ZA ZA2010/02465A patent/ZA201002465B/en unknown
- 2010-04-09 DO DO2010000101A patent/DOP2010000101A/es unknown
- 2010-04-09 US US12/757,089 patent/US8212032B2/en active Active
- 2010-05-06 CO CO10054262A patent/CO6270285A2/es active IP Right Grant
- 2010-05-11 CR CR11423A patent/CR11423A/es unknown
- 2010-08-11 HK HK10107690.6A patent/HK1141211A1/xx unknown
-
2014
- 2014-02-05 HR HRP20140105AT patent/HRP20140105T1/hr unknown
- 2014-02-18 CY CY20141100122T patent/CY1114865T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
MA30932B1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase | |
TNSN07022A1 (fr) | Derives de pyridine | |
TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
MA31419B1 (fr) | Derives de pyridine | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
MA29926B1 (fr) | Derives de pyrazine | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
MA26697A1 (fr) | Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant | |
MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
MA32231B1 (fr) | Composés organiques | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
MA31894B1 (fr) | Composes organiques | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA30652B1 (fr) | Composes organiques | |
MA31873B1 (fr) | Inhibiteurs de la peptide déformylase | |
MA32887B1 (fr) | Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete |